Gut Bacteria Compound ImP Tied to Alzheimer's Risk — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Wisconsin-Madison researchers published a Nature Communications study linking imidazole propionate (ImP), a compound made by gut bacteria, to increased Alzheimer's risk, harmful brain protein buildup, and faster cognitive decline.
- In mouse experiments, ImP reaching the brain increased accumulation of abnormal beta amyloid and tau proteins — the two hallmarks of Alzheimer's disease that ultimately kill neurons, according to co-author Federico Rey.
- Blood samples from nearly 1,200 participants in the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center showed higher ImP levels correlated with dementia biomarkers and steeper declines on cognitive tests over time.
- A genetic variation associated with substantially elevated ImP levels — carried by about 43% of study participants — was previously linked to higher Alzheimer's risk in large genetic studies, possibly because the variant may impair how effectively the kidneys clear ImP from the blood.
- Histidine, the essential amino acid from which gut bacteria produce ImP, is abundant in protein-rich foods like eggs and red meat, making dietary elimination impractical; co-author Barbara Bendlin compared the long-term therapeutic goal to statins that lower cholesterol to reduce heart disease risk.
Why it matters: With roughly 43% of study participants carrying a genetic variant that elevates blood ImP, a large fraction of the population could theoretically benefit from a future ImP-reducing drug. The work reframes Alzheimer's as partly a metabolic condition rooted in gut chemistry — not solely brain pathology — and gives drug developers a concrete molecular target analogous to cholesterol for heart disease.
Ask SkimNews
